On the one hand, there is considerable interindividual variability in patient sensitivity to glucocorticoids, partly attributable to GR genetic polymorphisms and heterogeneity in GR expression levels and signaling pathways across different breast cancer subtypes, which may lead to inconsistent efficacy at standard doses. The gene discussed is NR3C1; the disease is breast cancer.